A Controlled Study on Fighting Against Anxiety in Older People Through an Educational Audio Programme. (ECLIPSE)

November 4, 2026 updated by: Centre Hospitalier de Cannes Simone Veil

EXPLORATORY, PROSPECTIVE, MONO-CENTRIC, RANDOMISED, CONTROLLED, OPEN LABEL, STUDY EVALUATING BENEFITS OF A DIGITAL AUDIO PROGRAMME ON ANXIETY IN AGED CARE HOMES' RESIDENTS

In residential care homes for the elderly, safeguarding the mental and emotional health of aged people is a key factor in their well-being and the quality of care they receive. Among these disorders, anxiety plays a central role. Furthermore, in aged people, anxiety is frequently associated with other psychological and functional vulnerabilities, notably depression and sleep disorders, with which it frequently interacts. Taken together, these factors contribute to a cycle of emotional, cognitive and functional vulnerability that can impair the well-being of residents in care homes. In light of these challenges, non-pharmacological interventions (NPIs), which have the potential to reduce anxiety and depression and improve sleep, represent a particularly promising complementary approach and are attracting growing interest in the care of aged people living in care homes. The Simone Veil Gerontology Institute and Care Home of Cannes Hospital wishes to offer its residents a sound immersion programme as part of their standard care. The audio content is sourced from the SOMEO Life digital platform, an audio-guided application accessible via wireless headphones connected to a tablet or smartphone, allowing for individual or group use. This application offers pre-recorded sessions on relaxation, guided breathing and sophrology tailored to aged people living in care homes. In this context, this study aims to explore and evaluate, within a pragmatic and institutional framework, the benefits of an audio-guided sound immersion programme (SOMEO Life platform) on the current levels of anxiety among residents living in care homes. Depressive symptoms, sleep disorders and the use of anti-anxiety medication will also be assessed.

An exploratory, prospective, single-centre, randomised, controlled, open-label study evaluating the benefits of a digital audio programme on anxiety in elderly people in care homes is implemented. Forty patients will be recruited (twenty per groups) and followed-up during 3 months.

Primary objective is to determine whether adding an audio-guided sound immersion programme to standard care reduces the current level of anxiety (state anxiety) in patients in residential care homes for the elderly. Study endpoint is State-Trait Anxiety Inventory (STAI-Y), specifically the State Anxiety (Y-A) subscale.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • France
    • Alpes-maritime
      • Cannes, Alpes-maritime, France, 06400
        • Centre Hospitalier de Cannes Simone Veil
        • Contact:
        • Principal Investigator:
          • Charlotte PREVENT, Psychologist

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Residents who have been living in the care home for more than 2 months; · - A Mini Mental State Examination (MMSE) score of ≥ 20/30*, obtained in routine clinical practice within the 6 months prior to enrolment;
  • Patients with sufficient French language understanding, as assessed by the investigators
  • Patient's consent to participate in the study;
  • For patients under guardianship, curatorship or judicial protection, consent from the legal representative.
  • Social security scheme affiliation

Exclusion Criteria:

  • Patients with hearing loss who do not wear a hearing aid or whose hearing impairment prevents them from making effective use of the audio equipment;
  • Patients who, in the investigator's opinion, are unable to understand the objectives of the study or meet its criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: control group: standard programme

"Standard" programme usually available for patients: organised on a group basis: cognitive stimulation workshops, leisure activities (outings, shows or films), inter-generational workshops (meetings with children), inter-care home workshops (meetings with other residents), soft gym, craft or creative workshops, relaxation and sophrology workshops, and choral
Other: Standard programme

"Standard" programme usually available for patients: organised on a group basis: cognitive stimulation workshops, leisure activities (outings, shows or films), inter-generational workshops (meetings with children), inter-care home workshops (meetings with other residents), soft gym, craft or creative workshops, relaxation and sophrology workshops, and choral

Other Names:
  • Usual care programme
Experimental: experimental group: digital audio programme
  • usual programme available for patients: organised on a group basis: cognitive stimulation workshops, leisure activities (outings, shows or films), inter-generational workshops (meetings with children), inter-care home workshops (meetings with other residents), soft gym, craft or creative workshops, relaxation and sophrology workshops, and choral
  • two Audio immersion workshops added to weekly usual programme
Other: Standard programme

"Standard" programme usually available for patients: organised on a group basis: cognitive stimulation workshops, leisure activities (outings, shows or films), inter-generational workshops (meetings with children), inter-care home workshops (meetings with other residents), soft gym, craft or creative workshops, relaxation and sophrology workshops, and choral

Other Names:
  • Usual care programme
Other: digital audio programme

A non-pharmaceutical, digital sound immersion solution designed to improve the wellbeing of elderly people in care homes. The app, developed by SOMEO Solutions, offers structured audio programmes incorporating verbal guidance and a soothing soundscape. The audio content can be accessed via a mobile device without the need to download an app, and the audio is played through wireless earphones or headphones connected to a transmitter The platform can be accessed via a QR code or a dedicated URL, without the need to download anything or create an account. Access is anonymous. The playback equipment can be standard headphones (or earphones) or a UHF wireless headphone kit - over-ear, closed-back, with individually adjustable volume, and compatible with hearing aids.

Other Names:
  • group sound immersion workshop

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
State-Trait Anxiety Inventory (STAI-Y) A-section Scale
Time Frame: From enrollment to the end of programme at 3months

State-Trait Anxiety Inventory (STAI-Y), in its State Anxiety (Y-A) section, measured at two timepoints:

  • baseline record (timepoint 1) at initiation visit V0 or first interventionnal visit V1
  • end of follow-up record (timepoint 2) at 3months post V1 Score range: [20-80]. outcome is the score difference: end of follow-up record minus baseline record
From enrollment to the end of programme at 3months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Centre Hospitalier de Cannes Simone Veil

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Réadapta 2C Centre de recherche en psychologie et neurosciences UMR 7077 AMU CNRS
Entité de Recherche Territoriale AZUR (06)

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Charlotte PREVENT, Psychologist, Centre Hospitalier de Cannes Simone Veil

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 2, 2027

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 2, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 4, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 4, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 10, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 10, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 4, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2026-A01994-47
  • CHC-PI/2026-03 (Other Identifier: Centre Hospitalier de Cannes Simone Veil)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

data are own by CENTRE HOSPITALIER DE CANNES SIMONE VEIL, please contact sponsor for further information

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings